论文部分内容阅读
目的观察沙美特罗/氟替卡松吸入剂治疗稳定期重度慢性阻塞性肺疾病(COPD)的临床疗效。方法60例重度COPD患者随机分为试验组和对照组,各30例。常规处理有劝导戒烟、注射流感疫苗。基本治疗为口服氨茶碱片0.1g/次,3次/日,氨溴索片,30mg/次,3次/日。试验组加沙美特罗/氟替卡松50μg/250μg,l吸/次,2次/日,疗程3个月。治疗前后测定生活质量评分及第1秒钟用力呼气量(FEV1)、FEV1/用力肺活量(FVC)、FEV1占预计值百分比。结果54例患者最终完成试验,试验组28例,对照组26例,治疗前、后试验组生活质量评分明显改善(P<0.05);肺功能FEV1、FEV1/FVC、FEV1占预计值百分比均明显改善(P<0.05)。治疗后两组间比较,差异有统计学意义(P<0.05)。结论沙美特罗/氟替卡松吸入剂治疗COPD疗效肯定,值得临床进一步推广应用。
Objective To observe the clinical efficacy of salmeterol / fluticasone inhalation in the treatment of stable chronic obstructive pulmonary disease (COPD). Methods Sixty patients with severe COPD were randomly divided into experimental group and control group, with 30 cases in each. There are advised to quit smoking routine, flu vaccination. The basic treatment for oral aminophylline tablets 0.1g / time, 3 times / day, ambroxol, 30mg / time, 3 times / day. Test group gatifloxacol / fluticasone 50μg / 250μg, l suction / times, 2 times / day, treatment for 3 months. The quality of life scores, FEV 1, FEV 1 / FVC and FEV 1 as a percentage of the predicted value were measured before and after treatment. Results The final test was completed in 54 patients. The test group had 28 cases and the control group with 26 cases. The quality of life scores of the experimental group were significantly improved (P <0.05) before and after treatment. The percentage of FEV1, FEV1 / FVC and FEV1 Improve (P <0.05). After treatment, the difference between the two groups was statistically significant (P <0.05). Conclusion Salmeterol / fluticasone inhalation for the treatment of COPD positive effect, it is worth further clinical application.